Heron Therapeutics, Inc.
HRTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $65.1M
$0.34
▲ +4.21%
P/E
-1.81
Mkt Cap
$65.1M
52-Wk Range
$0.30–$1.58
52-Week Range
$0.30 - $1.58
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 73.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary Biochronomer extended-release delivery technology enabling multi-day/week dosing
- Established commercial products (SUSTOL, CINVANTI) with FDA approval and market presence
- Specialized focus on underserved oncology and perioperative care markets with limited competition
- Patent-protected formulations and delivery mechanisms providing durable competitive moats
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Stable outlook
Expansion of SUSTOL and CINVANTI market penetration in oncology centers and hospitals
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-24.2% over 3m
Quality
Excellent
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying HRTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 10, 2026
Reported EPS of -$0.03 vs -$0.01 consensus (-500.0% surprise). Revenue of $37.7M vs $42.2M expected (-10.7%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-500.0%
Revenue trend · last 8Q
—
+19%
+12%
+3%
+16%
-0%
-11%
+1%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$32.8M
$40.8M
$38.9M
$37.2M
$38.2M
$40.6M
$34.7M
$37.7M
Margins · last 8Q
Gross
69.3%
Operating
-5.4%
Profit
-14.6%
Wall Street consensus
2 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 11, 2026
vs Industry
How HRTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related